Cartiva Treats First US Patient in Thumb OA Study

By Julie A. Vetalice

The first U.S. patient has been treated in GRIP 2, a multi-center study evaluating Cartiva's Synthetic Cartilage Implant (SCI) to treat first carpometacarpal (CMC) joint osteoarthritis at the base of the thumb.

GRIP 2 is comparing SCI to a ligament reconstruction tendon interposition comparator in an estimated 74 patients in the U.S. and U.K.

Cartiva SCI, a hydrogel polymer implant, gained FDA premarket approval to treat great toe arthritis in mid-2016. The procedure is intended to preserve normal joint anatomy, allowing for conventional surgery in the future if needed. The CMC application is available in Canada and the EU.

Sources: Cartiva, Inc.; ORTHOWORLD Inc.

Product Labels: Orthobiologic Soft Tissue Repair

Tags: Product Launch